Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. (Q50903830)

25 March 2018

title

Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. (English)

1 reference

25 March 2018

author

Ton J Rabelink

6

1 reference

25 March 2018

Françoise Carlotti

object named as

F Carlotti

7

0 references

author name string

J H Ellenbroek

1

1 reference

25 March 2018

H A M Töns

2

1 reference

25 March 2018

M J A Westerouen van Meeteren

3

1 reference

25 March 2018

N de Graaf

4

1 reference

25 March 2018

M A Hanegraaf

5

1 reference

25 March 2018

E J P de Koning

8

1 reference

25 March 2018

publication date

16 June 2013

1 reference

25 March 2018

published in

Diabetologia

1 reference

25 March 2018

volume

56

1 reference

25 March 2018

issue

9

1 reference

25 March 2018

page(s)

1980-1986

1 reference

25 March 2018

https://scigraph.springernature.com/pub.10.1007/s00125-013-2957-2

exact match

0 references

cites work

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

The effects of glucagon-like peptide-1 on the beta cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Perspective: Postnatal pancreatic beta cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Expansion of beta-cell mass in response to pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagon-like peptide-1 and myocardial protection: more than glycemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Topologically heterogeneous beta cell adaptation in response to high-fat diet in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

GLP1 and cancer: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-013-2957-2

Glucagonlike peptide I (7-37) actions on endocrine pancreas

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23771206

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23771206

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23771206

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00125-013-2957-2

1 reference

25 March 2018

PubMed ID

23771206

1 reference

25 March 2018